VFY · ASX

Vitrafy Life Sciences Ltd. (ASX:VFY)

AU$1.75

 0.0 (0.0%)
ASX:Live
09/05/2025 01:36:36 PM
HALO Ords GROWTH AUS All-Consensus All-Companies
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

VFY Overview

VFY Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Very Strong

Earnings

Very Strong

Growth

Earnings

Very Strong

Dividends

Very Strong

Quality

Capital Efficiency

Very Strong

Balance Sheet

Very Strong

About VFY

Website

N/A

Telephone

61.3.4331.9974

Address

South Melbourne Level 4 96-100 Albert Road Melbourne, Victoria (VIC) 3205

Description

N/A

VFY Price Chart

Key Stats

Market Cap

n/a

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 1.08 - 2.1

Trade Value (12mth)

AU$10,489.00

1 week

-5.41%

1 month

62.04%

YTD

0%

1 year

0%

All time high

2.10

Key Fundamentals

EPS 3 yr Growth

N/A

EBITDA Margin

N/A

Operating Cashflow

N/A

Free Cash Flow Return

N/A

ROIC

N/A

Interest Coverage

N/A

Quick Ratio

N/A

Other Data

Shares on Issue (Fully Dilluted)

N/A

HALO Sector

Healthcare

Next Company Report Date

03-Sep-25

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

VFY Announcements

Latest Announcements

Date Announcements

02 May 25

Vitrafy Q3 FY25 Investor Presentation

×

Vitrafy Q3 FY25 Investor Presentation

02 May 25

Release of Securities from Mandatory Escrow

×

Release of Securities from Mandatory Escrow

29 April 25

Q3 FY25 Quarterly Activities Report and Appendix 4C

×

Q3 FY25 Quarterly Activities Report and Appendix 4C

28 April 25

Vitrafy Q3 FY25 Investor Briefing

×

Vitrafy Q3 FY25 Investor Briefing

16 April 25

USAISR successful Phase 1 Blood Platelet study

×

USAISR successful Phase 1 Blood Platelet study

15 April 25

Notification regarding unquoted securities - VFY

×

Notification regarding unquoted securities - VFY

08 April 25

Application for quotation of securities - VFY

×

Application for quotation of securities - VFY

27 March 25

Release of Securities from Mandatory Escrow

×

Release of Securities from Mandatory Escrow

20 March 25

NWR Virtual Healthcare Conference Presentation

×

NWR Virtual Healthcare Conference Presentation

19 March 25

Vitrafy to present at NWR Virtual Healthcare Conference

×

Vitrafy to present at NWR Virtual Healthcare Conference

19 March 25

Change of Director's Interest Notice

×

Change of Director's Interest Notice

18 March 25

Vitrafy Awarded Industry Growth Program Grant

×

Vitrafy Awarded Industry Growth Program Grant

28 February 25

Notification of cessation of securities - VFY

×

Notification of cessation of securities - VFY

21 February 25

Application for quotation of securities - VFY

×

Application for quotation of securities - VFY

10 February 25

Application for quotation of securities - VFY

×

Application for quotation of securities - VFY

06 February 25

FY25 Half Year Results Presentation

×

FY25 Half Year Results Presentation

06 February 25

FY25 Appendix 4D and Half Year Report

×

FY25 Appendix 4D and Half Year Report

04 February 25

Vitrafy Half Year FY25 Investor Briefing

×

Vitrafy Half Year FY25 Investor Briefing

31 January 25

Release of Securities from Mandatory Escrow

×

Release of Securities from Mandatory Escrow

31 January 25

Q2 FY25 Quarterly Activities Report and Appendix 4C

×

Q2 FY25 Quarterly Activities Report and Appendix 4C

12 December 24

Revised Securities Trading Policy

×

Revised Securities Trading Policy

10 December 24

Change of Director's Interest Notice

×

Change of Director's Interest Notice

27 November 24

Becoming a substantial holder from RYD

×

Becoming a substantial holder from RYD

26 November 24

Initial Director's Interest Notice

×

Initial Director's Interest Notice

26 November 24

Initial Director's Interest Notice

×

Initial Director's Interest Notice

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

0.00%

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

VFY Shortsell

Frequently Asked Questions

The current share price of Vitrafy Life Sciences Ltd. (VFY:ASX) is AU$1.75.
The 52-week high share price for Vitrafy Life Sciences Ltd. (VFY:ASX) is AU$2.10.
The 52-week low share price for Vitrafy Life Sciences Ltd. (VFY:ASX)? is AU$1.08.
Vitrafy Life Sciences Ltd. (VFY:ASX) does not pay a dividend.
Vitrafy Life Sciences Ltd. (VFY:ASX) does not pay a dividend.
Vitrafy Life Sciences Ltd. (VFY:ASX) has a franking level of 0.0%.
Vitrafy Life Sciences Ltd. (VFY:ASX) is classified in the Healthcare.
logo
Login
Company
Company
Important

Get the latest insights and hot tips delivered right to your inbox

App Store Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.